PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data presented at the European Association for the Study…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
